跳至主要内容
临床试验/IRCT201107216907N2
IRCT201107216907N2已完成未知

Cinnarizine versus placebo in pediatric migraine prophylaxis

Tehran University of Medical Sciences0 个研究点目标入组 68 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
5 years 至 17 years(—)
性别
All

入选标准

  • 1. Patients with migraine (with or without aura), diagnosed according to the International Headache society criteria. 2. Patients who had one or more migraine attack per week ; or sever dysfunction in daily and school activities during prospective baseline phase. 3. Headaches must not relate to any known structural brain lesion or other systemic conditions. Exclusion criteria: 1. Chronic headache, complications of migraine or other migraine variant. 2. Children and adolescents with Focal neurologic deficit. 3. History of diagnosed sensitivity to cinnarizine . 4. Patients who showed sever adverse effect to the study treatment drugs (in the double-blind phase of the study). 5. Serious comorbidities (hepatic, renal, cardiovascular or thyroid disease). 6. Patients who took prophylactic therapy for migraine within 4 weeks before study.

排除标准

  • 未提供

研究者

相似试验